パトリック・ギルジャム

Patrick Giljum joined BioTechLogic in 2004 as the Head of Operations. He has over 27 years of experience in biopharmaceutical process development and cGMP manufacturing of clinical and commercial supplies, supporting multiple Drug Substance and Drug Product technologies. Most recently, he supported the process validation, registration, and commercialization of an adjuvanted vaccine filed in both the US and Europe.

Prior to joining BioTechLogic, Mr. Giljum directed the manufacturing operations for clinical supply, registration, and ongoing commercial supply of biopharmaceutical products within Pfizer (and the former Pharmacia Corporation), including the process validation, registration, and commercialization of Somavert®.

From 1993-1999, Mr. Giljum was involved in the development of multiple Cytokine protein products for G.D. Searle, a division of Monsanto, including molecular biology, synthesis and purification, technology relocation, process validation, and the production of clinical and launch supplies.

From 1991 to 1993, Mr. Giljum supported the molecular biology and fermentation technology for the commercialization of Posilac®, Bovine Somatotropin, with Monsanto, Animal Science Division.

Mr. Giljum received his B.A. in Biology/Microbiology and completed graduate studies in Medical Physiology and Molecular Biology at St. Louis University.